フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
TORONTO and HOUSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...
TORONTO and HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...
Patient with melanoma, having failed dual check-point inhibitor therapy, achieved a complete response...
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into...
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a...
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009...
MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target...
TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...
ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to...
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024...
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024...
Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated...
100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial...
MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
サインアップして広告なしのエクスペリエンスを体験してください
今すぐ試してください
広告を残す